Novel genes, including **NPVF**, identified as potential autoimmune targets in hypocretin-deficient narcolepsy type 1

Narcolepsy type 1 (NT1) is a debilitating sleep-wake disorder characterized by a profound deficiency of hypocretin (also known as orexin) neurons. Despite strong associations with the HLA-DQB1*06:02 allele and links to the H1N1 pandemic, the precise pathophysiological mechanisms leading to the selective destruction of these neurons remain largely unknown. Current understanding points towards an autoimmune etiology, but the specific autoantigen, distinct from hypocretin itself, that triggers this immune response has yet to be identified, representing a critical gap in understanding NT1 pathogenesis.

Researchers employed an in silico method to identify novel candidate antigens for the autoimmune response in NT1. They utilized a combination of multiple publicly available datasets derived from human brain tissue of healthy individuals. The study mapped the expression profile of hypocretin and categorized genes based on their expression pattern and association with hypocretin expression. This approach aimed to pinpoint genes that share an expression pattern with hypocretin neurons, making them plausible targets for an autoimmune attack leading to cell destruction.

The in silico analysis successfully identified 15 candidate genes as potentially relevant targets in the development of NT1, exhibiting varying degrees of confidence regarding their involvement. Among these, six candidate genes demonstrated significantly higher expression specifically within hypocretin cells when compared to other cells in the hypothalamus. > The gene NPVF (neuropeptide FF-amide peptide precursor) emerged as the most promising candidate among the identified genes, suggesting a strong potential for its involvement as an autoantigen. These findings provide crucial new insights into the molecular landscape of hypocretin neurons and potential triggers for their loss in NT1.